Assuming these medications increase cardiac ACE-2 in clinical settings in a similar manner to animal experiments, and also increased cardiac ACE-2, would mean more viral infection in the heart, and SARS-CoV-2-related myocarditis would be a common complication for COVID-19 patients under ACEi/ARB. Here, ACE2 is linked to COVID-19.